高级检索
当前位置: 首页 > 详情页

Anti-inflammatory effects of Weiyan I decoction against gastric ulcers in a rat model via inhibition of p38 mitogen-activated protein kinases signaling

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China. [2]School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
出处:
ISSN:

关键词: Gastric ulcers mitogen-activated protein kinases SB203580 anhydrous ethanol Weiyan I decoction

摘要:
Gastric ulcer (GU) is a common gastrointestinal disease that can lead to complications such as bleeding, perforation and even cancer. Weiyan I Decoction (WYI) is an effective Chinese medicine prescription against GU. This study aimed to explore the therapeutic mechanism of WYI in GU. WYI constituents were analyzed via ultra-high-performance liquid chromatography-mass spectrometry. SD rats were divided into control, model, lansoprazole (30mg/kg), SB203580 (2mg/kg), WYI (10.8g/kg, 5.4g/kg and 2.7g/kg) groups. GU was induced using ethanol or indomethacin post-WYI pre-administration. Ulcer area, histopathology, serum prostaglandin E2 (PGE2), nitric oxide (NO), gastric tissue cytokines and mitogen-activated protein kinases (MAPKs) were evaluated. Gastric mucus content and pH were determined in the pylorus ligation rat model. Administration of WYI reduced ulcer areas and inflammatory infiltration, elevated serum PGE2 and reduced NO. It decreased gastric tumor necrosis factor-α (TNF-α), interleukin (IL)-1β and IL-6 levels and inhibited p38 and JNK phosphorylation. The p38 MAPK inhibitor SB203580 significantly reduced the ulcer area, gastric cytokines (TNF-α, IL-1β and IL-6), serum NO and elevating serum PGE2. WYI had no significant impact on gastric acid and mucus secretion. WYI demonstrated gastroprotective effects in GU through anti-inflammatory actions and p38 MAPK pathway inhibition, providing insights for innovative GU therapies.

基金:
语种:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 4 区 医学
小类 | 4 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 药学
JCR分区:
出版当年[2021]版:
Q4 PHARMACOLOGY & PHARMACY
最新[2023]版:
Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Shenzhen Traditional Chinese Medicine Hospital, The Fourth Clinical College of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号